A simple blood test

screening for colorectal cancer and advanced precancerous lesions

SEPTIN9 Gene Methylation Testing:

  • Simple blood draw
  • No special preparation needed
  • No stool sample to collect
  • No changes to your diet or medicines

Introducing

SPOT-MAS CRC

A blood test detecting cancer‑associated DNA changes (methylation of the SEPTIN9 gene) released into the bloodstream by colorectal tumors

0

Sensitivity*

0

Specificity*

(*) The sensitivity for the advanced precancerous lesion (APL) group is 54.29%. Wu et al. (2024). BMC Cancer.

Find out:
Download Leaflet

Colorectal Cancer (CRC) Burden

New CRC cases annually1
0 M
Deaths each year1
0 K
Most common cancer worldwide1
# 0
Cause of cancer death1
# 0

Colorectal cancer (CRC) is common—but highly preventable and treatable when found early.

5-year Survival Rates For
Colorectal Cancer At Different Stages2
  1. Sung H, CA Cancer J Clin. 2021.  2. American Cancer Society. Survival Rates for Colorectal Cancer. 2026.

What is SPOT-MAS CRC test?

A blood test that looks for tiny, cancer‑associated DNA changes (methylation of the SEPTIN9 gene) that can be released into your bloodstream by colorectal tumors

Single Blood Tube Requirement
 

PCR Mixture

 
Methylation
Detection

 

Sensitivity*
0 %
Specificity
0 %

(*) The sensitivity for the advanced precancerous lesion (APL) group is 54.29%.

Disclaimer: SPOT‑MAS CRC is a screening blood test for average‑risk adults and does not diagnose colorectal cancer. A positive result requires follow‑up colonoscopy; a negative result does not rule out cancer or replace routine screening recommended by your clinician.

SPOT-MAS portfolio Scope Technology
SPOT-MAS 10 Multi-omics features of 10 cancer types: Breast, Lung, Liver-Biliary tract, Colorectum, Stomach, Ovary, Pancreas, Esophagus, Endometrium, Head & Neck
  • Multi AI machine learning and deep learning models
  • Cell-free Multi-omics ATLAS
SPOT-MAS Lung Multiple lung-specific DNA features
SPOT-MAS CRC Pro Multiple colorectum-specific DNA features
SPOT-MAS CRC Septin9 gene methylation status
  • Multiplex Real-time PCR

Who should consider SPOT-MAS CRC?

  • Adults 45–75 at average risk: People without symptoms and without a significant family history of colorectal cancer who need routine screening
  • People who decline or cannot undergo colonoscopy: Individuals who are unwilling or unable to have a colonoscopy but still want to be screened.
  • Individuals between colonoscopy check‑ins: Individuals who want an additional, convenient screen between recommended colonoscopy intervals (as advised by a clinician).
Note: If you have bowel symptoms or are at higher risk (e.g., strong family history, prior polyps/CRC, or inflammatory bowel disease), talk to your clinician—you may need a different testing plan.

Gene Solutions JSC

186 - 188 Nguyen Duy Duong, Ward 2, District 10, Ho Chi Minh City, Vietnam

[email protected]

www.genesolutions.com

Scan here to learn more about colorectal cancer risk and the SPOT-MAS test.